MOLECULAR NEUROSCIENCEFocal transient ischemia increases APP-BP1 expression in neural progenitor cellsJoo, Yuyounga; Lee, Sang Hyungb; Ha, Sungjia; Hong, Bo-Hyuna; Kim, Joung-Hund; Suh, Yoo-Huna; Kim, Hye-Suna,c Author Information aDepartments of Pharmacology bNeurosurgery, Boramae Medical Center, Seoul cSeoul National University Bundang Hospital, Seoul National University, College of Medicine, Sungnam, GyeongGi dDepartment of Life Science, Pohang University of Science and Technology, Pohang, GyungBuk, Korea Correspondence to Professor Hye-Sun Kim, PhD, Department of Pharmacology, College of Medicine, Seoul National University, Seoul, 110-799, South Korea Tel: +82 2 740 8298; fax: +82 2 741 8298; e-mail: [email protected] Yuyoung Joo and Sang Hyung Lee equally contributed to this study Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (www.neuroreport.com). Received November 30, 2010 Accepted January 3, 2011 NeuroReport: March 30, 2011 - Volume 22 - Issue 5 - p 200-205 doi: 10.1097/WNR.0b013e32834449cf Buy SDC Metrics Abstract Amyloid precursor protein binding protein-1 (APP-BP1) binds to the carboxyl terminus of APP. In this study, we explored whether APP-BP1 expression is affected by focal transient cerebral ischemia induced by middle cerebral artery occlusion in Wistar rats. APP-BP1 expression was increased in the dentate gyrus of the hippocampus and in the subventricular zone of rats exposed to focal transient cerebral ischemia. In addition, APP-BP1 immunoreactivity overlapped with antidoublecortin and anti-5-bromo-2-deoxyuridine labeling. Focal transient cerebral ischemia has been reported earlier to induce neurogenesis in adult brains. The upregulation of APP-BP1 expression in neural progenitor cells after focal transient ischemia suggests that this protein contributes to the neurogenesis induced by transient ischemia and reperfusion. © 2011 Lippincott Williams & Wilkins, Inc.